Can ‘eugenics’ be defended?

In recent years, bioethical discourse around the topic of ‘genetic enhancement’ has become increasingly politicized. We fear there is too much focus on the semantic question of whether we should call particular practices and emerging bio-technologies such as CRISPR ‘eugenics’, rather than the more i...

Descripción completa

Detalles Bibliográficos
Autores principales: Veit, Walter, Anomaly, Jonathan, Agar, Nicholas, Singer, Peter, Fleischman, Diana S., Minerva, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321981/
https://www.ncbi.nlm.nih.gov/pubmed/34033008
http://dx.doi.org/10.1007/s40592-021-00129-1
_version_ 1783730951506886656
author Veit, Walter
Anomaly, Jonathan
Agar, Nicholas
Singer, Peter
Fleischman, Diana S.
Minerva, Francesca
author_facet Veit, Walter
Anomaly, Jonathan
Agar, Nicholas
Singer, Peter
Fleischman, Diana S.
Minerva, Francesca
author_sort Veit, Walter
collection PubMed
description In recent years, bioethical discourse around the topic of ‘genetic enhancement’ has become increasingly politicized. We fear there is too much focus on the semantic question of whether we should call particular practices and emerging bio-technologies such as CRISPR ‘eugenics’, rather than the more important question of how we should view them from the perspective of ethics and policy. Here, we address the question of whether ‘eugenics’ can be defended and how proponents and critics of enhancement should engage with each other.
format Online
Article
Text
id pubmed-8321981
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83219812021-08-19 Can ‘eugenics’ be defended? Veit, Walter Anomaly, Jonathan Agar, Nicholas Singer, Peter Fleischman, Diana S. Minerva, Francesca Monash Bioeth Rev Commentary In recent years, bioethical discourse around the topic of ‘genetic enhancement’ has become increasingly politicized. We fear there is too much focus on the semantic question of whether we should call particular practices and emerging bio-technologies such as CRISPR ‘eugenics’, rather than the more important question of how we should view them from the perspective of ethics and policy. Here, we address the question of whether ‘eugenics’ can be defended and how proponents and critics of enhancement should engage with each other. Springer International Publishing 2021-05-25 2021 /pmc/articles/PMC8321981/ /pubmed/34033008 http://dx.doi.org/10.1007/s40592-021-00129-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Commentary
Veit, Walter
Anomaly, Jonathan
Agar, Nicholas
Singer, Peter
Fleischman, Diana S.
Minerva, Francesca
Can ‘eugenics’ be defended?
title Can ‘eugenics’ be defended?
title_full Can ‘eugenics’ be defended?
title_fullStr Can ‘eugenics’ be defended?
title_full_unstemmed Can ‘eugenics’ be defended?
title_short Can ‘eugenics’ be defended?
title_sort can ‘eugenics’ be defended?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321981/
https://www.ncbi.nlm.nih.gov/pubmed/34033008
http://dx.doi.org/10.1007/s40592-021-00129-1
work_keys_str_mv AT veitwalter caneugenicsbedefended
AT anomalyjonathan caneugenicsbedefended
AT agarnicholas caneugenicsbedefended
AT singerpeter caneugenicsbedefended
AT fleischmandianas caneugenicsbedefended
AT minervafrancesca caneugenicsbedefended

Ejemplares similares